Ita Fitzgerald

1. FITZGERALD, Ita, BAYRAKTAR, Izgi, EIDEN, Birgit, GITTINS, Rosalind, MAGNI, Erica, HUMBERT-CLAUDE, Marie, MOLITSCHNIG, Lara-Turiya, DARM, Paula, WAKSMUNDZKA-WALCZUK, Anna, RIESENHUBER, Nikolaus, ŠTUHEC, Matej, TAŠKOVÁ, Ivana, HAHN, Martina. Comparative efficacy and safety of alternatives to sodium valproate in the management of bipolar affective disorder in people of child-bearing age : a narrative review by the European Society of Clinical Pharmacy's mental health specialist interest group. International journal of clinical pharmacy. [Online ed.]. Apr. 2025, vol. 47, str. 666–675. ISSN 2210-7711. https://link.springer.com/article/10.1007/s11096-025-01919-x, Digitalna knjižnica Univerze v Mariboru – DKUM, DOI: 10.1007/s11096-025-01919-x. [COBISS.SI-ID 237509635]
projekt: J3-50127 Intervencije kliničnega farmacevta v psihiatričnih bolnišnicah pri bolnikih z duševnimi motnjami: vpliv na težave povezane z zdravili; financer: ARIS
projekt: Open Access funding provided by the IReL Consortium

2. TAŠKOVÁ, Ivana, GITTINS, Rosalind, RIESENHUBER, Nikolaus, ŠTUHEC, Matej, HAHN, Martina, ŠAFÁŘOVÁ, Nicole, FIALOVA, Daniela, FITZGERALD, Ita. Developing a core competency framework for psychiatric pharmacists : a Europe‑wide e‑Delphi consensus study conducted by the European Society of Clinical Pharmacy Mental Health Special Interest Group. International journal of clinical pharmacy. [Online ed.]. 13 str., ilustr. ISSN 2210-7711. https://link.springer.com/article/10.1007/s11096-026-02213-0, DOI: 10.1007/s11096-026-02213-0. [COBISS.SI-ID 291863555]
projekt: This research was supported by the project New Technologies for Translational Research in Pharmaceutical Sciences (NETPHARM) (project ID CZ.02.01.01/00/22_008/0004607), co-funded by the European Union. Additional support was provided by the institutional research programme Cooperatio (KSKF-1 research group led by Assoc. Prof. Daniela Fialová) at the Faculty of Pharmacy, Charles University, Czech Republic.
projekt: J3-50127 Intervencije kliničnega farmacevta v psihiatričnih bolnišnicah pri bolnikih z duševnimi motnjami: vpliv na težave povezane z zdravili; financer: ARIS